SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Werner SC. Classification of thyroid diseases. Report of the committee on nomenclature. American Thyroid Association. J Clin Endocrinol Metab. 1969; 29: 860862.
  • 2
    Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 1896; 2: 104107.
  • 3
    Nogueira CR, Brentani MM. Triiodothyronine mimics the effect of estrogen in breast cancer cell lines. J Steroid Biochem Mol Biol. 1996: 59: 271279.
  • 4
    Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene. 2002; 21: 761768.
  • 5
    Vonderhaar BK, Greco AE. Lobulo-alveolar development of mouse mammary glands is regulated by thyroid hormones. Endocrinology. 1979; 104: 409418.
  • 6
    Brinton LA, Hoffman DA, Hoover R, Fraumeni JF Jr. Relationship of thyroid disease and use of thyroid supplements to breast cancer risk. J Chron Dis. 1984; 37: 877893.
  • 7
    Simon MS, Tang MT, Bernstein L, et al. Do thyroid disorders increase the risk of breast cancer? Cancer Epidemiol Biomarkers Prev. 2002; 11: 15741578.
  • 8
    Franceschi S, La Vecchia C, Negri E, Parazzini F, Boyle P. Breast cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer. 1990; 26: 781785.
  • 9
    Altieri A, Tavani A, Gallus S, et al. Correspondence re: Simon et al. Do thyroid disorders increase the risk of breast cancer? 11:1574–1578, 2002. Cancer Epidemiol Biomarkers Prev. 2002; 12: 684686.
  • 10
    Ellerker AG. Thyroid disorders and breast cancer. A causal connection? Med Press. 1956; 235: 280282.
  • 11
    Itoh K, Maruchi N. Breast cancer in patients with Hashimoto's thyroiditis. Lancet. 1975; 2: 11091112.
  • 12
    Shering SG, Zbar AP, Moriarty M, McDermott EWM, O'Higgins NJ, Smith PPA. Thyroid disorders and breast cancer. Eur J Cancer Prev. 1996; 5: 504506.
  • 13
    Smith PPA, Shering SG, Kilbane MT, et al. Serum thyroid peroxidase autoantibodies, thyroid volume and outcome in breast carcinoma. J Clin Endocrinol Metab. 1998; 83: 27112716.
  • 14
    Roberts GP, Ladenson PW. Hypothyroidism. Lancet. 2004; 363: 793803.
  • 15
    Gail MH, Benichou J. Validation studies on a model for breast cancer risk. J Natl Cancer Inst. 1994; 86: 573575.
  • 16
    Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362: 419427. Erratum in: Lancet. 2003; 362: 1160.
  • 17
    Venturi S, Donati FM, Venturi A, et al. Role of iodine in evolution and carcinogenesis of thyroid, breast and stomach. Adv Clin Pathol. 2000; 4: 1117.
  • 18
    Kilbane MT, Ajjan RA, Weetman AP, et al. Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. J Clin Endocrinol Metab. 2000; 3: 12451250.
  • 19
    Vonderhaar BK, Tang E, Lyster RR, Nascimento MC. Thyroid hormone regulation of epidermal growth factor receptor levels in mouse mammary glands. Endocrinology. 1986; 119: 580585.
  • 20
    Bhattacharya A, Vonderhaar BK. Specific binding proteins for 3, 5, 30-triiodothyronine in mouse mammary epithelium. J Cell Biol. 1977; 75: 47a.
  • 21
    Selliti D, Tseng Y, Latham K. Nuclear thyroid hormone receptors in C3H/HeN mouse mammary glands and spontaneous tumors. Cancer Res. 1983; 43: 10301038.
  • 22
    Smallridge RC, Latham KR. Nuclear thyroid hormone receptor in human breast tumors. Clin Res. 1980; 28: 421.
  • 23
    Cerbon M-A, Pichon M-F, Milgrom E. Thyroid hormone receptors in human breast cancer. Cancer Res. 1981; 41: 41674173.
  • 24
    Kupper FC, Schweigert N, Ar Gall E,et al. Iodine uptake in Laminariales involves extracellular, haloperoxidase-mediated oxidation of iodide. Planta. 1998; 207: 163171.
  • 25
    van de Vijver M, van de Bersselaar R, Devilee P, et al. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol. 1987; 7: 20192023.
  • 26
    Li Z, Meng ZH, Chandrasekaran R, et al. Biallelic inactivation of the thyroid hormone receptor beta 1 gene in early stage breast cancer. Cancer Res. 2002; 62: 19391943.
  • 27
    Silva JM, Dominguez G, Gonzalez-Sancho JM, et al. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene. 2002; 21: 43074316.
  • 28
    Martinez MB, Ruan M, Fitzpatrick LA. Altered response to thyroid hormones by breast and ovarian cancer cells. Anticancer Res. 2000; 20: 41414146.
  • 29
    Gonzalez-Sancho JM, Figueroa A, Lopez-Barahona M, et al. Inhibition of proliferation and expression of T1 and cyclin D1 genes by thyroid hormone in mammary epithelial cells. Mol Carcinog. 2002; 34: 2534.
  • 30
    Glass CK. Differential recognition of target genes by nuclear receptor monomers, dimmers and heterodimers. Endocrine Rev. 1994; 15: 391407.
  • 31
    Yen PM, Sugawara A, Chin WW. Triiodothyronine (T3) differentially affects T3-receptor/retinoic acid receptor and T3-receptor/retinoid X receptor heterodimer binding to DNA. J Biol Chem. 1992; 267: 2324823252.
  • 32
    D'Cruz CM, Moody SE, Master SR, et al. Persistent parity-induced changes in growth factors, TGF-β3, and differentiation in the rodent mammary gland. Mol Endocrinol. 2002; 16: 20342051.